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Abstract
This paper introduces the concept of personalized
physiological medicine that is specifically directed at the
needs of the critically ill patient. This differs from the
conventional view of personalized medicine,
characterized by biomarkers and gene profiling, instead
focusing on time-variant changes in the pathophysiology
and regulation of various organ systems and their cellular
and subcellular constituents. I propose that personalized
physiological medicine is composed of four pillars
relevant to the critically ill patient. Pillar 1 is defined by
the frailty and fitness of the patient and their
physiological reserve to cope with the stress of critical
illness and therapy. Pillar 2 involves monitoring of the key
physiological variables of the different organ systems and
their response to disease and therapy. Pillar 3 concerns
the evaluation of the success of resuscitation by
assessment of the hemodynamic coherence between
the systemic and microcirculation and parenchyma of
the organ systems. Finally, pillar 4 is defined by the
integration of the physiological and clinical data into a
time-learning adaptive model of the patient to provide
feedback about the function of organ systems and to
guide and assess the response to disease and therapy. I
discuss each pillar and describe the challenges to
research and development that will allow the realization
of personalized physiological medicine to be practiced at
the bedside for critically ill patients.
Background
Randomized controlled clinical trials (RCTs) have failed
to provide needed direction for the diagnosis and treat-
ment of the critically ill patient. Such trials, based on the
idea that evidence for the treatment of individual
patients can only be achieved by demonstrating efficacy
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of one treatment modality over another in large groups
of patients, have not been able to demonstrate effective
therapies; at best, the trials (e.g., TRIC, SPLIT, SAFE,
PROCESS, ARISE, CHEST, PROWESS, SEPSISPAM,
etc.) have shown no difference between groups. These
results often lead, in practice, to the mistaken conclusion
that there is no difference between the interventions. A
more correct conclusion could be that such RCTs, by
design, are unable to demonstrate differences in hetero-
geneous intensive care patients because the physiology
of individual patients at the bedside indeed shows differ-
ences between various interventions. These shortcom-
ings of RCTs have led to the suggestion that such trials
should be abandoned to focus on a more personalized
approach for identifying the optimal therapy for each in-
dividual patient [1]. This concept has been referred to as
“personalized medicine” and has been mainly associated
with the measurement of pharmacological biomarkers
and genetic profiling with the goal of identifying person-
alized therapy to result in improved survival benefit (e.g.,
[2]). However, additional requirements and concepts
may be needed for personalized medicine if this concept
is to be applied to the critically ill patient. The time-
variant changes in (patho)physiology in response to the
wide range of disorders with complex interactions
between failing organ systems being treated with a var-
iety of drugs and organ-supporting devices distinguishes
critically ill patients from other categories of patients
(e.g., oncology and cardiology). These considerations
lead to the idea that a new form of personalized medi-
cine may need to be designed to meet the specific needs
of the critically ill patient.
Personalized physiological medicine
Conventional personalized medicine based on genetic
profiling and pharmacological biomarkers will need
development if they are to be applied to the practical
needs of the critically ill patient. The main challenges of
this form of personalized medicine will be to obtain gen-
etic and biomarkers in a semicontinuous manner and to
link this information to specific organ function allowing
targeted therapy to be realized. The genetic profile and
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transcription factors of the critically ill patient continu-
ously change over time [3]. Levels of pharmacological
biomarkers also change continuously over time [4], and
the currently available biomarkers of sepsis have been
found to lack specificity and sensitivity [5]. These
aspects of conventional personalized medicine have
prompted the idea that considering physiological vari-
ables as biomarkers may provide an essential addition to
the needs of the critically ill patient because they relate
more closely to the aims of intensive care medicine in
terms of providing physiological recovery and organ sup-
port [6, 7]. Such a physiological approach to personal-
ized medicine must be focused on the phenotype of the
patient as well as on the functional properties of their
organs and ultimately their cells as they change over
time in response to disease and therapy. From this per-
spective, I propose here the concept of personalized
physiological medicine as being more appropriate in
achieving these aims. In doing so, I identify four pillars
of personalized physiological medicine on which this
concept is based (Fig. 1): 1) fitness and frailty; 2) organ
function and response to therapy; 3) hemodynamic
coherence; and 4) integration and feedback.
Pillar I: fitness and frailty
The first pillar of personalized physiological medicine is
the assessment of fitness and frailty of the patient to
determine their physiological reserve. Although obvi-
ously not applicable to critically ill patients, the gold
standard for determining fitness is cardiopulmonary
exercise testing (CPT), in which cardiovascular stress is
imposed by incremental amounts of work and maximum
oxygen consumption. Consequently the aerobic thresh-
old is considered as the best index of cardiorespiratory
fitness [8] but this has not been applied to critically ill
patients. Inadequate exercise has been shown to be a
risk factor for sepsis mortality, particularly in diabetics
[9]. Exercising critically patients using a bedside cycle
ergometer has been shown in survivors to result in im-
proved 6-min walking distance, isometric quadriceps
force, and the subjective feeling of well-being following
discharge [10]. In experimental studies in septic rats, ex-
ercise protected organs from damage and lowered in-
flammatory mediators [11]. Increasingly, muscle is being
recognized as a key hormone secreting organ where
myokines, hormones secreted by the exercising muscle,
are being shown to play a central role in resolving a host
of disease states including cancer and diabetes [12]. In-
deed, Montgomery and colleagues demonstrated that
muscle wasting during critical illness is directly related
to organ failure [13]. That is why developing objective
measures of fitness in bed-ridden patients and mainten-
ance of muscle mass by developing exercise modalities
during critical illness must be recognized as an
important aim in this pillar of personalized physiological
medicine.
Extended lack of fitness can translate into frailty, a
condition in which homeostatic mechanisms begin to
fail, resulting in reductions in the physiological reserve
of the neural, renal, skeletal, respiratory, cardiovascular,
endocrine, immune, and coagulation systems when chal-
lenged by stress [14], such as in critical illness. Several
studies have identified phenotypes associated with frailty,
including measures related to physical activity, energy,
nutritional status, strength, and cognition [15, 16]. The
evaluation of frailty as a phenotype in the critically ill
patient has been shown in several studies to be of special
relevance in the prediction of intensive care unit (ICU)
survival (e.g., [17]); frail survivors of critical illness have
been shown to experience greater impairment in health-
related quality of life and disability compared with those
who are not frail [18]. Frailty, defined as a physiologic
loss of reserve capacity and resistance to stressors [16,
19], has been quantified in several studies [15]. It is clear
that continuous measures of fitness, frailty, and physio-
logical reserve, along with coexisting comorbidity and
primary disease, are key input variables defining the
phenotype of the patient and therefore represent the first
pillar of personalized physiological medicine.
Pillar II: organ function
The second pillar of personalized physiological medicine
involves the function of the organ systems and their re-
sponse to therapy. Evaluation of the regulatory capacity
of the organ systems to stress factors is central because
a loss of this regulatory capacity occurs in advance of
physical injury to the parenchymal cells associated with
upregulation of conventional pharmacological bio-
markers. Loss of regulatory capacity represents a win-
dow of opportunity for treatment prior to the
occurrence of irreversible injury requiring long-term re-
generation [6]. Here, providing a physiological challenge
to the patient and measuring organ response at the bed-
side is a central concept in evaluating physiological re-
serve. For instance, the dobutamine challenge test to
evaluate the regulatory capacity of the β-adrenergic sys-
tem in septic patients was introduced by Vallet and co-
workers, who were able to predict survival in septic pa-
tients by measuring the response to oxygen delivery,
consumption, and extraction [20]. A nonpharmacologi-
cal version of the dobutamine stress test was explored
by Kimmoun et al. to assess the efficiency of cardiac
adaptation to septic shock by measuring cardiac con-
tractility reserve-related parameters, including cardiac
index, double product, and cardiac power index during
the resuscitation procedure [21]. In this context, the
heart rate response is also a promising methodology to
assess the ability of the autonomic nervous system to
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regulate cardiovascular responses and assess interorgan
communication [22, 23]. The future challenge will be
how to therapeutically treat the regulatory capacity of
the β-adrenergic system to improve outcome.
Achieving optimal ventilation recruitment and avoid-
ing ventilator-induced lung injury are arguably the main
targets in achieving good ventilation-perfusion matching
and gas exchange during mechanical ventilation. Adjust-
ment of ventilator settings, assessing deleterious effects
of often-used therapy, including fluid therapy and mech-
anical ventilation, and evaluating the direct effects of
therapies directed at the lung itself, such as nebulization
of antibiotics [24], anticoagulants [25], anti-
inflammatory [26] and vasoactive compounds [27], truly
requires a personalized approach in which bedside lung
function evaluation is essential. Although several lung
function parameters are available at the bedside (e.g., air-
way resistance, tidal volume, end-expiratory lung vol-
ume, intrinsic positive end-expiratory pressure (PEEP),
compliance, dead space, and volumetric capnography)
and novel clinical methodologies such as electric imped-
ance tomography are being developed [28], essential
lung function parameters directly related to the capacity
of the lung to achieve gas exchange are lacking. A need
Fig. 1 The four pillars of personalized physiological medicine. Pillar I is measurement of the fitness and frailty of the patient and their
physiological reserve and fitness to deal with the physiological stress of critical illness. Pillar II concerns measurement of the function of organ
systems and their response to therapy as well as their functional capacity and reserve including the immunological, humoral and coagulatory
systems. Pillar III concerns the measurement of the hemodynamic coherence between the macro- and microcirculation and parenchymal cells in
response to resuscitation. The loss of hemodynamic coherence can be identified by observation of the microcirculation, where type 1 concerns
inflammation and infection-induced heterogeneous obstructions of microcirculatory flow, type 2 concerns hemodilution-induced loss of red
blood cell filled capillaries, type 3 concerns microcirculatory stasis induced by excessive vasopressor load or raised venous pressures, and type 4
concerns tissue edema (red cells are well oxygenated and blue cells are hypoxic cells; taken from [35] with permission). Pillar IV is the integration
and feedback of the various elements of the personalized physiological medicine modules to provide input in an integrative and time variant
holistic manner to identify and assess the success of therapy and severity of organ and cellular dysfunction, as well as identifying the essential
parameters in need of correction
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exists for the quantitative assessment of functional
residual capacity (FRC), inhomogeneity of ventilation,
and ventilation-perfusion matching. Indeed the import-
ance of such measurements have been demonstrated in
experimental models of acute lung injury (ALI) where
the effects of respiratory movements could be directly
observed in exposed mice lungs using dark-field intravi-
tal microscopy [29]. Measurement of these parameters
has classically required the quantitative measurement of
the washout of inert indicator gases requiring the use of
complex mass spectrometry [30] at the bedside [31].
More practical measurement of these parameters at the
bedside is currently under investigation (e.g., [32]). In
addition to these volumetric measures, more compre-
hensive physical properties of the lung tissue itself are
required beyond conventional dynamic compliance and
airway resistance measures. Such information can be
obtained, for example, by the forced oscillation
technique in which the frequency-dependent impedance
of the complete pulmonary system can be obtained,
providing detailed information about the mechanical
properties of the lung (e.g., [33]). It is clear from these
considerations that there is a need to further develop
techniques to measure these pulmonary parameters and
to integrate them into a single monitoring platform to
meet the requirements of this pillar of personalized
physiological medicine.
Measuring kidney function is a specific challenge in
intensive care management. This has typically been lim-
ited to the measurement of urine production and cre-
atinine levels, both of which are considered inadequate
indicators of kidney function. As a result, there has been
a surge in renal pharmacological biomarker research.
Although these biomarkers have been effective in identi-
fying renal injury, they have not yet proven successful in
guiding therapy. Their time-variant changes and their
sensitivity only to advanced renal injury led us to
develop the concept of physiological biomarkers of acute
kidney injury (AKI) [6]. We proposed that such physio-
logical biomarkers be related to renal hemodynamics
and regulation, microcirculation and oxygenation, and
tubular function because these are expected to be altered
in advance of an injury, thereby identifying a window of
therapeutic efficacy. Consistent with these concepts,
Ronco and co-workers developed methodologies to
measure renal physiological reserve, which was defined
as the capacity of the kidney to increase the rate of
glomerular filtration in response to a physiological stress;
they proposed the administration of a fixed protein load
for this purpose [34]. Using a similar concept to measure
the functional capacity of the kidney, Chawla and co-
workers administered furosemide to stimulate urine pro-
duction and found that the furosemide stress test was
much more sensitive in predicting stage 3 AKI than
pharmacological biomarkers [35]. From these examples
it is clear that there is a concerted effort to establish a
functional platform to more comprehensively monitor
organ function and assess the capacity to regulate func-
tional reserve in real time as an essential goal for per-
sonalized physiological medicine. Recent advanced in
ultrasound such as contrast-enhanced ultrasound may
make such sensitive monitoring of the renal microcircu-
lation feasible in patients [36].
Pillar III: hemodynamic coherence
Resuscitation aims at normalizing systemic
hemodynamic variables, such as stroke volume or blood
pressure, with the expectation that a parallel improve-
ment will occur in the perfusion and oxygenation of the
microcirculation feeding the tissue beds of the organ
systems. Homeostatic coupling between the systemic cir-
culation and the microcirculation is essential for such an
expectation to be met; in addition to the primary dis-
ease, resuscitation fluids and medications themselves can
adversely affect this regulation. We have termed the
required coupling between the macro- and microcircula-
tion essential for successful resuscitation based on the
correction of systemic hemodynamic variables as
“hemodynamic coherence” [37]. Loss of hemodynamic
coherence can occur if the factors affecting the microcir-
culation are not corrected by the resuscitation procedure
focused on correction of the macrocirculation by resus-
citation following shock. Such factors affecting the
microcirculation can include immunological and/or fac-
tors affecting endothelial, leucocyte, and red blood cell
function. In this context, its manifestation should be
regarded as a dynamic process depending on the interac-
tions between disease, therapy, and time. Whether the
correction of systemic hemodynamic variables achieves
adequate microcirculatory and tissue perfusion is often
unknown and may manifest at the bedside as the patient
being unresponsive. Such a situation prompts the clin-
ician to administer even more fluids and medications,
potentially causing harm. Assessment of the presence or
absence of hemodynamic coherence requires the simul-
taneous measurement of the response of the macro- and
the microcirculation. The microcirculation can be effect-
ively visualized in the sublingual area using hand-held
vital microscopy (e.g., [38]), which allows the parallel
improvement in the microcirculation to resuscitation
efforts based on the response of systemic parameters to
be verified [39]. Identification of the presence or absence
of hemodynamic coherence and the response of the
microcirculation to therapy forms the third pillar of per-
sonalized physiological medicine because it assesses the
physiological coupling between the various compart-
ments in the hierarchy of the circulation to achieve uni-
form resuscitation. Loss of hemodynamic coherence at
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the level of the microcirculation can be divided into four
types (Fig. 1). Type 1 loss of hemodynamic coherence is
characteristic of states of sepsis, in which inflammatory
mediators and oxidative and nitrosative stress factors
cause endothelial and erythrocyte injury resulting in
obstruction of the capillaries. This causes a heteroge-
neous microcirculatory flow and functional shunting in
parts of the microcirculation, resulting in reduced oxy-
gen extraction capacity characteristic of sepsis [40]. Type
2 loss of hemodynamic coherence occurs when an
excessive volume of fluids is given in an attempt to cor-
rect systemic variables, such as stroke volume and blood
pressure. While systemic variables may be normalized,
hemodilution causes reduced viscosity and dilution of
the blood, both of which cause a reduction in capillary
filling. This increases the diffusion distances between
oxygen-carrying erythrocytes and tissue cells, thereby
reducing the oxygen delivery capacity of the microcircu-
lation and its oxygen extraction capacity [39]. Type 3
loss of hemodynamic coherence is the condition where
high levels of vasopressors intended to improve blood
pressures can paradoxically cause constriction of micro-
circulatory blood flow [41]. Similarly, microcirculatory
impediment of flow can occur when high venous pres-
sures are targeted, resulting in microcirculatory flow
restriction due to tamponade [42]. Type 4 loss of
hemodynamic coherence occurs as a result of edema
(e.g., in burns [43] and in malaria [44]) in which leaky
vessels also cause increased diffusion distances and a
reduction in oxygen extraction.
Pillar IV: feedback and integration
Personalized physiological medicine directly relates to
the practice of intensive care in supporting organ func-
tion and restoring homeostasis. Concepts from systems
and control engineering, in which integration and feed-
back are central for the control of complex systems [22],
are important to consider. To this end, I define the
fourth pillar of personalized physiological medicine as
the integration of the modules in the aforementioned
three pillars to provide feedback on the functional activ-
ity of different physiological compartments, to identify
the functional state and stability of the system, and to
provide practical feedback to guide therapy and ensure
resolution of the unstable patient prior to the develop-
ment of irreversible states of critical illness.
Intensivists are confronted with an overwhelming
amount of patient data, including historical clinical
information as well as continuous online data regarding
the condition of the patient, which changes from
moment to moment [45]. Decisions based on assessment
of these data are based on clinical experience as well as
evidence from trials and knowledge of the literature;
however, this assessment relies more on the subjective
judgment of the physician rather on a strict analysis of
data. Various initiatives have been formulated to
integrate and simplify the vast amount of data being
generated from the patient, describing both the condi-
tion of the patient (e.g., APACHE, SAPS and SOFA) and
that of specific organ systems (e.g., AKIN and KDIGO
for AKI). Currently, more sophisticated predictive meth-
odologies are being developed, making use of complex
mathematics such as chaos and complexity theory [46].
Almost without exception, these methods are used to
evaluate the severity of disease without providing any
insight into the physiologic basis for the condition of the
patient. These approaches neither identify a given
physiological parameter in need of correction nor iden-
tify optimal therapy and provide feedback for a thera-
peutic maneuver in a goal-directed manner.
For these reasons, the fourth pillar of personalized
physiological medicine requires not only a predictive
environment to describe the condition of the patient,
but a more comprehensive mathematical model directly
related to the function of the organ systems from a sys-
tems engineering and integrative systems physiological
perspective. Here, measuring the interactions between
the various physiological compartments, including the
immune and humoral systems as well as the cellular and
ultimately even the genetic profile, stemming from the
previous three pillars of personalized physiological medi-
cine should provide a holistic description of the physio-
logical state of the patient and, more importantly,
provide practical feedback for identifying the need,
response, and success of therapy. Such an approach
requires adaptive modeling in which the model is con-
tinuously responding, considering time-variant changes
and providing an optimal model for patient care (e.g.,
[47]). Central to the model should be the measures of
organ function of pillar 2 to provide the needed feedback
to evaluate organ and therapy support and interactions
between the different physiological compartments. In
this way, the model should be capable of assessing the
stability of the system so that successful weaning from
an assisted mode can be accomplished, in which therapy
and organ-supporting devices are successful in achieving
eventual independent organ function. It can even be
conceived that such models can become closed loop
control systems for control of specific parts of the
support system (e.g., [48]).
Conclusion
Personalized medicine is a developing trend for the
future of intensive care medicine. However, the practical
implementation of this concept, if limited to the use of
genetic screening and pharmacological biomarkers, how-
ever appealing, is still in need of considerable develop-
ment. I therefore propose a personalized physiological
Ince Critical Care 2017, 21(Suppl 3):308 Page 31 of 73
approach which I argue is much more suited to the
requirements of critically ill patients. I have presented
four pillars of personalized physiological medicine to
address the full spectrum of this idea. This classification
allows a modular approach, as its various aspects are
under development in sometimes unrelated areas of crit-
ical care medicine. Integration of the concepts will pro-
vide a true challenge for the future, requiring
collaboration between clinicians, physiologists, and engi-
neers; the realization of bedside instruments to practice
personalized physiological medicine remains a real chal-
lenge to industry. Nevertheless, I anticipate that the road
map outlined in this paper may provide a conceptual
framework within which critically ill patients will benefit
from the promises of personalized medicine.
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